Human Longevity has appointed Sally Howard as head of regulatory affairs and policy. She will lead all efforts related to federal and state regulatory oversight for the company. Howard comes to Human Longevity from the US Food and Drug Administration, where she most recently served as senior advisor and acting chief of staff to the FDA commissioner. Before that she spent two years as FDA deputy commissioner for policy, planning, and legislation. Prior to her positions at the FDA, Howard spent two years as chief of staff at the US Department of Health and Human Services.
Maria Fe Paz
Rosetta Genomics has appointed Maria Fe Paz as interim chief medical officer with plans to transition her to chief medical officer upon receipt of a valid work visa that supports her planned relocation to the US. Paz joins Rosetta Genomics from Labceutics were she was the founder-president and the Diaceutics Group where she served as chief medical officer. Prior to joining Diaceutics and founding Labceutics, she served as head of translational medicine and scientific development at Zeltia. Paz's earlier experience includes founding and serving as the scientific-medical consultant for Epicure Molecular, serving as head of the epigenetics unit at the Spanish National Cardiovascular Center, and she was founder and director of molecular and genetic diagnostics laboratories in Hospital de Madrid.
Exosome Diagnostics has appointed John Boyce as its Chief Executive Officer. Boyce is a co-founder of GnuBio and served as president and CEO of the company until its acquisition by Bio-Rad, after which he headed the Bio-Rad Digital Biology Center. Prior to his work at GnuBio, Boyce served as head of business development and scientific collaborations at Helicos. He was also senior director of commercial development at Parallele Biosciences and senior director of sales and marketing at Sequenom.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.